Trial Profile

A First-in-human, Phase I, Open-Label Study of EMB-07, a Bi-specific Antibody Anti-CD3 and Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Patients With Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EMB-07 (Primary)
Indications Adenocarcinoma; Bladder cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Lung cancer; Lymphoma; Male breast cancer; Mantle-cell lymphoma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Uterine cancer
Focus Adverse reactions; First in man
Sponsors Epimab Biotherapeutics

21 Sep 2023 Planned number of patients changed from 75 to 150.
21 Sep 2023 Planned End Date changed from 31 Jul 2025 to 31 Mar 2026.
21 Sep 2023 Planned primary completion date changed from 31 Mar 2025 to 31 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com